Progression of disease within 24 months of initial therapy (POD24) detected incidentally in imaging does not necessarily indicate worse outcome-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Progression of disease within 24 months of initial therapy (POD24) detected incidentally in imaging does not necessarily indicate worse outcome

Published:2020-07-09 Issue:11 Volume:61 Page:2645-2651
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Bitansky Guy¹,Avigdor Abraham¹²,Vasilev Elena²,Zlotnick Maya²,Ribakovsky Elena²,Benjamini Ohad¹²,Nagler Arnon¹²,Kedmi Meirav¹²³

Affiliation:

1. Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

2. Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel

3. The Mina & Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1786554

Reference22 articles.

1. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

2. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience

3. Long-term outcome and mortality trends in early-stage, Grade 1–2 follicular lymphoma treated with radiation therapy

4. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

5. Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus 131Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnosis, management and follow‐up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance;Internal Medicine Journal;2024-08

2. Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma;Leukemia & Lymphoma;2023-08-11

3. Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden;HemaSphere;2023-02-23

4. The role of surveillance computed tomography in patients with follicular lymphoma;Therapeutic Advances in Hematology;2022-01

5. Follicular Lymphoma: Refining Prognostic Models and Impact of Pod-24 in Clinical Outcomes;Clinical Lymphoma Myeloma and Leukemia;2021-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3